CTIS2023-510196-59-00招募中1 期
A Phase 3, open-label, randomized, controlled study to evaluate the immune response, safety and reactogenicity of RSVPreF3 OA investigational vaccine when co-administered with a COVID-19 mRNA vaccine (Omicron XBB.1.5) in adults aged 50 years and above. - 217848
适应症
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 入组人数
- 850
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 65+（—）
- 性别
- All
入选标准
- •Participants, who, in the opinion of the investigator, can and will comply with the requirements of the protocol (e.g., completion of the diary cards, return for follow-up visits). INC#1, Written or witnessed informed consent obtained from the participant (participant must be able to understand the informed consent) prior to performance of any study-specific procedure. INC#2, A male/female of =50 YOA at the time of the first study intervention administration. INC#3, Participants who are medically stable in the opinion of the investigator at the time of first vaccination. Participants with chronic stable medical conditions with or without specific treatment, such as diabetes, hypertension or cardiac disease, are allowed to participate in this study if considered by the investigator as medically stable. INC#4, Participants living in the general community or in an assisted-living facility that provides minimal assistance, such that the participant is primarily responsible for self-care and activities of daily living. INC#5, Participants who have received previously a SARS-CoV-2 vaccine, being administered at least 3 months prior to study vaccination. INC#6, Female participants of non-childbearing potential may be enrolled in the study. Non childbearing potential is defined as hysterectomy, bilateral oophorectomy, bilateral salpingectomy, and post-menopause. INC#7, Female participants of childbearing potential may be enrolled in the study if the participant. INC#8 ?has practiced adequate contraception from 1 month prior to study intervention administration and agreed to continue adequate contraception for at least 1 month after the last vaccination. ?has a negative pregnancy test on the day of and prior to study intervention administration.
排除标准
- •History of any reaction or hypersensitivity likely to be exacerbated by any component of the study interventions, including a known history of severe allergic reaction (e.g., anaphylaxis). EXC#1, Any other clinical condition that, in the opinion of the investigator, might pose additional risk to the participant due to participation in the study. EXC#10, Recent SARS-CoV-2 infection within 3 months prior to the COVID-19 vaccine dose administration. Timelines to be determined from symptoms onset or positive COVID-19 test (if infection was asymptomatic). EXC#11, Use of any investigational or non-registered product (drug, vaccine or invasive medical device) other than the study interventions during the period beginning 30 days before the first dose of study interventions and ending 30 days after the last vaccine administration, or their planned use during the study period. EXC#12, Planned administration of a vaccine in the period starting 30 days before the first dose and ending 30 days after the last dose of study intervention(s) administration*, with the exception of inactivated and subunit influenza vaccines which can be administered up to 14 days before or from 14 days after the study vaccination. EXC#13, •Chronic administration of immune-modifying drugs (defined as more than 14 consecutive days in total) and/or planned use of long-acting immune-modifying treatments at any time up to the last blood sampling visit. EXC#14 ?Up to 3 months prior to the study intervention administration: oFor corticosteroids, this will mean prednisone equivalent = 20 mg/day. Inhaled and topical steroids are allowed. oAdministration of immunoglobulins and/or any blood products or plasma derivatives. ?Up to 6 months prior to study intervention administration: long-acting immune modifying drugs including among others immunotherapy (e.g., TNF-inhibitors), monoclonal antibodies and antitumoral medication., Administration of any SARS-CoV-2 vaccine during the 3 months preceding the study COVID-19 mRNA vaccine administration. EXC#15, Previous vaccination with licensed or investigational RSV vaccine. EXC#16, Concurrently participating in another clinical study, at any time during the study period, in which the participant has been or will be exposed to an investigational or a non-investigational intervention (drug/invasive medical device). EXC#17, Pregnant or lactating female participant. EXC#18, Female participant planning to become pregnant or planning to discontinue contraceptive precautions. EXC#19, Any confirmed or suspected immunosuppressive or immunodeficient condition, resulting from disease (e.g., current malignancy, human immunodeficiency virus) or immunosuppressive/cytotoxic therapy (e.g., medication used during cancer chemotherapy, organ transplantation, or to treat autoimmune disorders), based on medical history and physical examination (no laboratory testing required). EXC#2, History of chronic alcohol consumption and/or drug abuse as deemed by the investigator to render the potential participant unable/unlikely to provide accurate safety reports or comply with study procedures. EXC#20, Participation of any study personnel or their immediate dependents, family, or household members. EXC#21, Planned move during the study conduct that prohibits participation until study end. EXC#22, Bedridden participants. EXC#23, Any history of myocarditis or pericarditis. EXC#3, Recurrent history or uncontrolled neurological disorders or seizures. Participants wi
研究者
相似试验
进行中（未招募）
1 期
An open-label clinical trial evaluating enfortumab vedotin in combination with pembrolizumab versus chemotherapy alone in previously untreated locally advanced or metastatic urothelial cancerrothelial cancerMedDRA version: 20.0Level: LLTClassification code: 10046714Term: Urothelial carcinoma bladder Class: 10029104MedDRA version: 20.0Level: LLTClassification code: 10046723Term: Urothelial carcinoma ureter Class: 10029104MedDRA version: 20.0Level: LLTClassification code: 10046728Term: Urothelial carcinoma urethra Class: 10029104CTIS2023-503421-19-00Seagen Inc.1,422
进行中（未招募）
1 期
An open-label clinical trial evaluating enfortumab vedotin in combinationwith pembrolizumab versus chemotherapy alone in previously untreatedlocally advanced or metastatic urothelial cancerrothelial cancerMedDRA version: 20.0Level: LLTClassification code 10046714Term: Urothelial carcinoma bladderSystem Organ Class: 100000004864MedDRA version: 20.0Level: LLTClassification code 10046723Term: Urothelial carcinoma ureterSystem Organ Class: 100000004864MedDRA version: 20.0Level: LLTClassification code 10046728Term: Urothelial carcinoma urethraSystem Organ Class: 100000004864EUCTR2019-004542-15-DKSeagen Inc.860
进行中（未招募）
1 期
An open-label clinical trial evaluating enfortumab vedotin in combination with pembrolizumab versus chemotherapy alone in previously untreated locally advanced or metastatic urothelial cancerrothelial cancerMedDRA version: 20.0Level: LLTClassification code 10046714Term: Urothelial carcinoma bladderSystem Organ Class: 100000004864MedDRA version: 20.0Level: LLTClassification code 10046723Term: Urothelial carcinoma ureterSystem Organ Class: 100000004864MedDRA version: 20.0Level: LLTClassification code 10046728Term: Urothelial carcinoma urethraSystem Organ Class: 100000004864EUCTR2019-004542-15-CZSeagen Inc.760
进行中（未招募）
1 期
An open-label clinical trial evaluating enfortumab vedotin in combination with pembrolizumab with or without chemotherapy, versus chemotherapy alone in previously untreated locally advanced or metastatic urothelial cancerrothelial cancerMedDRA version: 20.0Level: LLTClassification code 10046714Term: Urothelial carcinoma bladderSystem Organ Class: 100000004864MedDRA version: 20.0Level: LLTClassification code 10046723Term: Urothelial carcinoma ureterSystem Organ Class: 100000004864MedDRA version: 20.0Level: LLTClassification code 10046728Term: Urothelial carcinoma urethraSystem Organ Class: 100000004864EUCTR2019-004542-15-FRSeattle Genetics, Inc.1,095
进行中（未招募）
1 期
Studio In aperto per valutare enfortumab vedotin in combinazione con pembrolizumab con o senza chemioterapia rispetto alla sola chemioterapia nel tumore uroteliale localmente avanzato o metastatico precedentemente non trattatorothelial cancerMedDRA version: 20.0Level: LLTClassification code 10046714Term: Urothelial carcinoma bladderSystem Organ Class: 100000004864MedDRA version: 20.0Level: LLTClassification code 10046723Term: Urothelial carcinoma ureterSystem Organ Class: 100000004864MedDRA version: 20.0Level: LLTClassification code 10046728Term: Urothelial carcinoma urethraSystem Organ Class: 100000004864EUCTR2019-004542-15-ITSEATTLE GENETICS, INC.1,095